Literature DB >> 15720551

Mapping binding residues in the Plasmodium vivax domain that binds Duffy antigen during red cell invasion.

Dhiraj Hans1, Priyabrata Pattnaik, Arindam Bhattacharyya, Ahmad Rushdi Shakri, Syed Shams Yazdani, Monal Sharma, Hyeryun Choe, Michael Farzan, Chetan E Chitnis.   

Abstract

Summary Plasmodium vivax depends on interaction with the Duffy antigen/receptor for chemokines (DARC) for invasion of human erythrocytes. The 140 kDa P. vivax Duffy-binding protein (PvDBP) mediates interaction with DARC. The receptor-binding domain of PvDBP maps to its N-terminal, cysteine-rich region, region II (PvRII), which contains approximately 300 amino acid residues including 12 conserved cysteines. Using surface plasmon resonance, we show that binding of PvRII to DARC is a high-affinity interaction with a binding constant (K(D)) of 8.7 nM. The minimal binding domain of PvRII has been previously mapped to a central 170-amino-acid stretch that includes cysteines 5-8. Here, we have used site-directed mutagenesis and quantitative binding assays to map amino acid residues within PvRII that make contact with DARC. Of the seven alanine replacement mutations that had an effect on binding, five were mutations in hydrophobic residues suggesting that hydrophobic interactions play a major role in the interaction of PvDBP with DARC. Genetic diversity studies have shown that six of the seven binding residues identified in PvRII are conserved in P. vivax field isolates, which provides support for their role in interaction with DARC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15720551     DOI: 10.1111/j.1365-2958.2005.04484.x

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  43 in total

1.  A recombinant dromedary antibody fragment (VHH or nanobody) directed against human Duffy antigen receptor for chemokines.

Authors:  Dorota Smolarek; Claude Hattab; Gholamreza Hassanzadeh-Ghassabeh; Sylvie Cochet; Carlos Gutiérrez; Alexandre G de Brevern; Rachanee Udomsangpetch; Julien Picot; Magdalena Grodecka; Kazimiera Wasniowska; Serge Muyldermans; Yves Colin; Caroline Le Van Kim; Marcin Czerwinski; Olivier Bertrand
Journal:  Cell Mol Life Sci       Date:  2010-05-11       Impact factor: 9.261

Review 2.  In silico studies on DARC.

Authors:  Alexandre G de Brevern; Ludovic Autin; Yves Colin; Olivier Bertrand; Catherine Etchebest
Journal:  Infect Disord Drug Targets       Date:  2009-06

3.  The crystal structure of P. knowlesi DBPalpha DBL domain and its implications for immune evasion.

Authors:  Amy M McHenry; John H Adams
Journal:  Trends Biochem Sci       Date:  2006-07-27       Impact factor: 13.807

4.  Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous plasmodium vivax strains in Papua New Guinean children.

Authors:  Jennifer L Cole-Tobian; Pascal Michon; Moses Biasor; Jack S Richards; James G Beeson; Ivo Mueller; Christopher L King
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

Review 5.  Red blood cell polymorphism and susceptibility to Plasmodium vivax.

Authors:  Peter A Zimmerman; Marcelo U Ferreira; Rosalind E Howes; Odile Mercereau-Puijalon
Journal:  Adv Parasitol       Date:  2013       Impact factor: 3.870

6.  Mapping epitopes of the Plasmodium vivax Duffy binding protein with naturally acquired inhibitory antibodies.

Authors:  Patchanee Chootong; Francis B Ntumngia; Kelley M VanBuskirk; Jia Xainli; Jennifer L Cole-Tobian; Christopher O Campbell; Tresa S Fraser; Christopher L King; John H Adams
Journal:  Infect Immun       Date:  2009-12-14       Impact factor: 3.441

7.  Efficient expression of tyrosine-sulfated proteins in E. coli using an expanded genetic code.

Authors:  Chang C Liu; Susan E Cellitti; Bernhard H Geierstanger; Peter G Schultz
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

Review 8.  Finding the sweet spots of inhibition: understanding the targets of a functional antibody against Plasmodium vivax Duffy binding protein.

Authors:  Francis B Ntumngia; Christopher L King; John H Adams
Journal:  Int J Parasitol       Date:  2012-10-12       Impact factor: 3.981

9.  The C-terminal segment of the cysteine-rich interdomain of Plasmodium falciparum erythrocyte membrane protein 1 determines CD36 binding and elicits antibodies that inhibit adhesion of parasite-infected erythrocytes.

Authors:  Min Mo; Hooi Chen Lee; Masayo Kotaka; Makhtar Niang; Xiaohong Gao; Jayasree Kaveri Iyer; Julien Lescar; Peter Preiser
Journal:  Infect Immun       Date:  2008-02-25       Impact factor: 3.441

10.  Immunogenicity of a synthetic vaccine based on Plasmodium vivax Duffy binding protein region II.

Authors:  Francis B Ntumngia; Samantha J Barnes; Amy M McHenry; Miriam T George; Jesse Schloegel; John H Adams
Journal:  Clin Vaccine Immunol       Date:  2014-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.